Sector
PharmaceuticalsOpen
₹340.55Prev. Close
₹338.9Turnover(Lac.)
₹93.54Day's High
₹343Day's Low
₹33352 Week's High
₹386.9552 Week's Low
₹226.9Book Value
₹53.25Face Value
₹1Mkt Cap (₹ Cr.)
3,428.99P/E
39.46EPS
8.59Divi. Yield
06 Sep 2023
12:00 AM
BookCloser
27 Jun 2024
12:00 AM
Board Meeting
Agenda : Audited Result
1 Sep 2023
12:00 AM
AGM
Announcement Date: 01 Sep, 2023
29 May 2023
12:00 AM
Dividend
Dividend Amount: 0.1
Record Date: 21 Sep, 2023
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 9.69 | 9.69 | 9.69 | 9.69 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 338.11 | 259.42 | 163.74 | 119.63 |
Net Worth | 347.8 | 269.11 | 173.43 | 129.32 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 779.15 | 487.69 | 357.75 | 300.96 |
yoy growth (%) | 59.76 | 36.32 | 18.86 | 22.58 |
Raw materials | -411.96 | -250.29 | -177.47 | -142.22 |
As % of sales | 52.87 | 51.32 | 49.6 | 47.25 |
Employee costs | -85.61 | -66.21 | -51.57 | -44.46 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 126.83 | 57.71 | 30.33 | 27.95 |
Depreciation | -17.13 | -16.3 | -8.35 | -4.3 |
Tax paid | -30.99 | -13.47 | -7.47 | -13.51 |
Working capital | 30.22 | -13.96 | 33.14 | 35.94 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 59.76 | 36.32 | 18.86 | 22.58 |
Op profit growth | 73.63 | 88.23 | 16.83 | 66.26 |
EBIT growth | 84.57 | 65.73 | 16.98 | 77.7 |
Net profit growth | 116.67 | 93.51 | 42.66 | 77.6 |
| Particulars (Rupees in Crores.) | Mar-2024 |
|---|---|
Gross Sales | 806.67 |
Excise Duty | 0 |
Net Sales | 806.67 |
Other Operating Income | 0 |
Other Income | 2.18 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Jayesh P Choksi
Whole Time Director & CEO
Pranav J Choksi
Whole-time Director
Pankaj Gandhi
Non-Exec. & Independent Dir.
Shreyas Patel
Company Sec. & Compli. Officer
Ami Naresh Shah
Non-Exec. & Independent Dir.
Gopal Daptari
Non-Exec. & Independent Dir.
Shrirang V Vadiya
Non-Exec & Non-Independent Dir
Balram Singh
Non-Exec. & Independent Dir.
Rabi Narayan Sahoo
Non-Exec. & Independent Dir.
Anusanjiv Aurora
Whole-time Director
Dilip Ghosh
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Gufic BioSciences Ltd
Summary
Gufic Biosciences (GBL) was incorporated in Jul84. The Company is a result of a reverse merger of itself with Central Finance. The promoters of GBL took over Central Finance at Rs 40-42 per share and then got GBL listed on BSE. Presently, the Company is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Choksi and Gandhi family, the promoters of GBL, have a long-standing presence in the pharma industry. In 1960, the family set up a joint venture company called Lyka Labs. In 1976, they decided to part ways and the Choksi family took over the manufacturing facility and the Gufic group of companies was born. Initially known as Gujarat Fine Chemicals, the first foray of the Gufic group was in the manufacture of various bulk drugs. The company later entered the formulation market. Currently, the overall profile of GBL comprises ethical products, herbal products, consumer products and bulk drugs that are sold in the domestic and the international markets. Over the past several years, the company have a known reputation of creating brands that have vaulted to leadership positions in the category in which they have been marketed. To mention a few names: Shapers (sanitary napkins), Onergy, and Stretch nil.In the year 2000, the company issued Bonus Equity Shares in proportion of five Equity shares for every two Equity shares held.Gufic has divested brands in the ethical pharma business in a sellers market.
Read More
What is the Gufic BioSciences Ltd share price today?
The Gufic BioSciences Ltd shares price on N/A is Rs.₹337.25 today.
What is the Market Cap of Gufic BioSciences Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gufic BioSciences Ltd is ₹3381.86 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Gufic BioSciences Ltd?
The PE and PB ratios of Gufic BioSciences Ltd is 39.46 and 6.38 as of 22 Jul ‘24
What is the 52 Week High and Low of Gufic BioSciences Ltd?
The 52-week high/low is the highest and lowest price at which a Gufic BioSciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Gufic BioSciences Ltd is ₹226.9 and ₹387 as of 22 Jul ‘24
What is the CAGR of Gufic BioSciences Ltd?
Gufic BioSciences Ltd's CAGR for 5 Years at 37.47%, 3 Years at 23.70%, 1 Year at 49.47%, 6 Month at -1.54%, 3 Month at 14.28% and 1 Month at -5.35%.
What is the shareholding pattern of Gufic BioSciences Ltd?
The shareholding pattern of Gufic BioSciences Ltd is as follows:
Promoters - 72.51 %
Institutions - 2.61 %
Public - 24.88 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
